Aurinia Pharmaceuticals Stock Market Value
| AUPH Stock | USD 8.86 0.01 0.11% |
| Symbol | Aurinia |
Aurinia Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aurinia Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aurinia Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aurinia Pharmaceuticals.
| 12/13/2022 |
| 12/02/2024 |
If you would invest 0.00 in Aurinia Pharmaceuticals on December 13, 2022 and sell it all today you would earn a total of 0.00 from holding Aurinia Pharmaceuticals or generate 0.0% return on investment in Aurinia Pharmaceuticals over 720 days. Aurinia Pharmaceuticals is related to or competes with Viking Therapeutics, Axsome Therapeutics, Madrigal Pharmaceuticals, Seres Therapeutics, Exelixis, TG Therapeutics, and BioXcel Therapeutics. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing th... More
Aurinia Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aurinia Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aurinia Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.11 | |||
| Information Ratio | 0.1285 | |||
| Maximum Drawdown | 13.43 | |||
| Value At Risk | (3.06) | |||
| Potential Upside | 5.07 |
Aurinia Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aurinia Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aurinia Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Aurinia Pharmaceuticals historical prices to predict the future Aurinia Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1449 | |||
| Jensen Alpha | 0.3795 | |||
| Total Risk Alpha | 0.0254 | |||
| Sortino Ratio | 0.1614 | |||
| Treynor Ratio | 0.6693 |
Aurinia Pharmaceuticals Backtested Returns
Aurinia Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Aurinia Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Aurinia Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Aurinia Pharmaceuticals' Downside Deviation of 2.11, risk adjusted performance of 0.1449, and Mean Deviation of 1.92 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aurinia Pharmaceuticals holds a performance score of 14. The firm shows a Beta (market volatility) of 0.7, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aurinia Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aurinia Pharmaceuticals is expected to be smaller as well. Please check Aurinia Pharmaceuticals' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Aurinia Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.77 |
Almost perfect reverse predictability
Aurinia Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Aurinia Pharmaceuticals time series from 13th of December 2022 to 8th of December 2023 and 8th of December 2023 to 2nd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aurinia Pharmaceuticals price movement. The serial correlation of -0.77 indicates that around 77.0% of current Aurinia Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.77 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 1.76 |
Aurinia Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Aurinia Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Aurinia Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Aurinia Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Aurinia Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Aurinia Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Aurinia Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Aurinia Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Aurinia Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Aurinia Pharmaceuticals Lagged Returns
When evaluating Aurinia Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Aurinia Pharmaceuticals stock have on its future price. Aurinia Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Aurinia Pharmaceuticals autocorrelation shows the relationship between Aurinia Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Aurinia Pharmaceuticals.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Aurinia Pharmaceuticals Correlation, Aurinia Pharmaceuticals Volatility and Aurinia Pharmaceuticals Alpha and Beta module to complement your research on Aurinia Pharmaceuticals. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Aurinia Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.